Abstract
Glycans are an essential structural component of Immunoglobulin G (IgG) that modulate its structure and function. However, regulatory mechanisms behind this complex posttranslational modification are not well known. Previous genome-wide association studies (GWAS) identified 29 genomic regions involved in regulation of IgG glycosylation, but only a few were functionally validated. One of the key functional features of IgG glycosylation is the addition of galactose (galactosylation). We performed GWAS of IgG galactosylation (N=13,705) and identified 16 significantly associated loci, indicating that IgG galactosylation is regulated by a complex network of genes that extends beyond the galactosyltransferase enzyme that adds galactose to IgG glycans. Gene prioritization identified 37 candidate genes. Using a recently developed CRISPR/dCas9 system we manipulated gene expression of candidate genes in the in vitro IgG expression system. Up- and downregulation of three genes, EEF1A1, MANBA and TNFRSF13B, changed the IgG glycome composition, which confirmed that these three genes are involved in IgG galactosylation in this in vitro expression system.
Competing Interest Statement
YSA is a cofounder and a co-owner of PolyOmica and PolyKnomics, private organizations providing research services in the field of quantitative, computational and statistical genomics. GL is the founder and CEO of Genos Ltd, a private research organization that specializes in high throughput glycomics analysis and has several patents in this field. AFH, TS, MPB, ITA, IG, JS, TP, BR, PT, FV and JK are employees of Genos Ltd. The remaining authors declare no competing interests
Funding Statement
This work was supported by the European Structural and Investment Funds grant for the Croatian National Centre of Competence in Molecular Diagnostics grant KK.01.2.2.03.0006, Croatian National Centre of Research Excellence in Personalized Healthcare grant KK.01.1.1.01.0010 and IRI "CardioMetabolic" grant KK.01.2.1.02.0321. AFH was supported by H2020-MSCA-ITN IMforFUTURE grant 721815. The work of AN was supported by the Ministry of Education and Science of the Russian Federation via the state assignment of the Novosibirsk State University (project "Graduates 2020"). The work of SZS and YSA was partially supported by the Research Program at the MSU Institute for Artificial Intelligence. The work of LK was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). The work of YL was supported by the German Research Foundation (grant KO_3598/4-2 to AK). The work of AK was supported by the German Research Foundation (grant KO_3598/5-1). RRCC, CW and MBS were supported by German Ministry of Education and Research (BMBF) and the State of Brandenburg DZD grants 82DZD00302 and 82DZD03D03. CW was also supported by SciLifeLab & Wallenberg Data Driven Life Science Program grant KAW 2020.0239. TwinsUK study was funded by Wellcome Trust grant 212904/Z/18/Z, Medical Research Council AIMHY grant MR/M016560/1, European Union H2020 grant 733100. TwinsUK and MM were also supported National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by local research ethics committees and all participants have given written informed consent. The "10001 Dalmatians" study was approved by the Ethics Committee of the Medical School, University of Split (approval ID: 2181-198-03-04/10-11-0008). The VIKING study was approved by the South East Scotland Research Ethics Committee, NHS Lothian (reference: 12/SS/0151). EPIC study was approved by the Ethics Committee of the State of Brandenburg, Germany. The Ethics Committee of the Bavarian Medical Association approved the KORA F4 study (EC No. 06068). TwinsUK study was approved by Guy's & St Thomas' Trust (GSTT) Ethics Committee. The ORCADES study was approved by the NHS Orkney Research Ethics Committee and the North of Scotland REC. The study protocol for GCKD cohort was approved by local institutional review boards at each participating academic institution and the data protection concept was reviewed by the data protection officer of the State of Hessen. LLS study was approved by The Medical Ethical Committee of the Leiden University Medical Center. The approval for the EGCUT study was granted by the Ethics Review Committee on Human Research at the University of Tartu.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The full summary statistics for discovery meta-analysis for G0, G1 and G2 traits is deposited at Zenodo (10.5281/zenodo.7227999). The summary statistics for gene expression levels in different tissues and cell types are available in the eQTLcatalogue project, DICE project and eQTLGen consortium. The summary statistics for other complex traits are available in publicly available resources, as listed in Table S5. Additional data related to this paper may be requested from the authors.
